Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of NMD670 in Adult Patients with Myasthenia Gravis
2023-507539-40-00Phase 2Authorised
- Sponsor
- NMD Pharma
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ignaseclant in myasthenia gravis (MG) (4 arms), sponsored by NMD Pharma. Primary endpoint: Change from baseline to day 21 in quantitative myasthenia gravis (QMG) total score. Planned start Jul 2024; status: authorised.
02
Drugs
ignaseclant
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-507539-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507539-40-00.